Rathna Yallapragada, MD
Internal Medicine · Willowbrook, ILNPI 1366455529
Payments from drug & device makers
What this record shows
21 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 56.8% of the total. Reporting peaked in 2023 at $1,969 and has fallen 95.2% since, to $95 in 2025.
Across 63 payments — averaging $49.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$2K
- AstraZeneca$203
- Amgen$161
- Novartis$126
- Teva Pharmaceuticals USA, Inc.$121
- Edwards Lifesciences$113
- plus $627 from 15 others
Across 114 payments — averaging $943.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$108K
What the payments were for
- Travel & lodging$1,41945%
- Food & beverage$1,71155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 9 | $1,778 |
| AstraZeneca | 7 | $203 |
| Amgen | 4 | $161 |
| Novartis | 7 | $126 |
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| Edwards Lifesciences | 1 | $113 |
| Novo Nordisk | 6 | $110 |
| Sanofi | 1 | $83 |
| Johnson & Johnson | 3 | $64 |
| Pfizer | 3 | $57 |
| Astellas Pharma US Inc | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Echosens North America, Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Medtronic | 1 | $17 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,130 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $64,870 |
| JardianceEmpagliflozin | 25 | $36,182 |
| OzempicSemaglutide | 23 | $31,937 |
| XareltoRivaroxaban | 18 | $29,215 |
| JanuviaSitagliptin Phosphate | 15 | $23,544 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,816 |
| BrilintaTicagrelor | 22 | $5,114 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $4,841 |
| MyrbetriqMirabegron | 11 | $3,610 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,536 |
| Atorvastatin Calcium | 278 | $3,389 |
| Metoprolol Succinate | 129 | $2,658 |
| Lisinopril | 199 | $2,277 |
| Rosuvastatin Calcium | 98 | $2,191 |
| Amlodipine Besylate | 193 | $2,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $64,870101 claims |
| Novo NordiskOzempic | $110 | $31,93723 claims |
| Johnson & JohnsonXarelto | $64 | $29,21518 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $23 | $16,81611 claims |
| AstraZenecaBrilinta | $203 | $5,11422 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $3,61011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Willowbrook
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.